USP7 and cancer: Given the recent study of USP7 as a deubiquitinating enzyme of HPV16 E7 and the promise shown by the highly specific USP7 inhibitors in in vivo models [147], these USP7 inhibitors could have therapeutic potential in HPV+ cancers.